✦ LIBER ✦

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

✍ Scribed by Ferrandina, Gabriella; Salutari, Vanda; Vincenzi, Bruno; Marinaccio, Marco; Naglieri, Emanuele; Loizzi, Vera; Carpano, Silvia; Amadio, Giulia; Tonini, Giuseppe; Scambia, Giovanni; Lorusso, Domenica

Book ID: 122386908
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 337 KB
Volume: 130
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.06.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan-Cetuximab-Bevacizumab as a Sa

Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

✍ Feliu Batlle, J.; Cuadrado, E.; Castro, J.; Caldés, T.; Belda, C.; Sastre, J.; B 📂 Article 📅 2011 🏛 S. Karger AG 🌐 English ⚖ 291 KB

A Phase II study of trabectedin single a

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

✍ Krasner, C N; McMeekin, D S; Chan, S; Braly, P S; Renshaw, F G; Kaye, S; Provenc 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 137 KB

Trabectedin as single agent in relapsed

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

✍ Campo, JosÃ© MarÃa; Sessa, Cristiana; Krasner, Carolyn N.; Vermorken, Jan B.; C 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 348 KB

8004 ORAL Safety and Efficacy Outcomes i

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

✍ Colombo, N.; Del Campo, J.M.; Sehouli, J.; Sessa, C.; Bidzinski, M.; Nieto, A.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Remission of a negative Her2/Neu overexp

Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy

✍ Cheng-Jeng Tai; Horng-Yuan Lo; Chung-Huei Hsu; Chen-Jei Tai; Wei-Min Liu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Treatment of recurrent ovarian cancer: a

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: The Memorial Sloan-Kettering Cancer Center experience

✍ Don S Dizon; Jakob Dupont; Sibyl Anderson; Paul Sabbatini; Amanda Hummer; Carol 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 128 KB